Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1599 participants
OBSERVATIONAL
2003-01-31
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The specific aims of the study are:
* To compare information obtained from fluorescence and reflectance spectroscopic measurements of the cervix with standard methods for detecting cervical pre-cancers.
* To validate previously developed algorithms for discriminating between normal and pre-cancerous tissue based on spectroscopic measurements.
* To evaluate the safety of spectroscopic measurement of cervical tissue.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
MEASUREMENT PROCEDURE:
The doctor will first place a vaginal speculum and then perform the LightTouch Ã'® procedure (that looks at tissue from the cervix using light). The doctor will use a fresh single use contact tube (a tube attached to the LightTouch device that helps hold it in place) and apply it gently to your cervix. This will transmit light much like a flashlight. The light will either reflect or bounce immediately off your cervix or it will enter the skin for less than a second, and then return back to the LightTouch device. Each reading will take about 5-7 minutes, and up to two readings may be taken. You may also be asked to repeat the experimental test the same day, for example 2 to 3 hours after the first test, as part of another experimental procedure to study whether the device gives the same result twice in a row on the same woman (a repeatability study). If you agree to a second (LightTouch) procedure you will again have placement of the contact tube applied gently to your cervix and another test will be taken. This could take another 5 to 7 minutes of your time.
Whether you agree to do one of the experimental tests or both of the tests, following the LightTouch experimental procedure(s), you will have a Pap smear of the endocervix (the doctor will use a small plastic brush remove cells from the endocervix canal). We will also test for human papilloma virus (HPV). HPV is a virus that is sexually transmitted is associated with abnormal Pap smears. The doctor will use two separate vials for these tests, one to take your Pap smear and the other to take more cells for an HPV test. Once the doctor takes your Pap smear and HPV test. The doctor will do the colposcopy exam using a colposcope to look at the cervix more closely to check for abnormal areas. The doctor will also apply acetic acid and Lugols if required. The doctor may also perform biopsy (remove one or more tissue samples you're your cervix) for later examination by a pathologist. If considered necessary, an ECC (Endocervical Curettage scraping of cells from the inside of the endocervix) will be performed if an abnormal area is seen.
A video image (camera) will be used to capture locations of abnormal areas and compare with the readings from the spectroscopic image. Your overall study participation time will be approximately 30 minutes. If you are asked to participate in second test and agree, it will take place directly after the first test. The spectroscopy portion in which measurements are taken takes 5 to 7 minutes to complete. If you have the second study procedure this will take an additional 15-30 minutes making your overall participation time up to 60 minutes (one hour). You may be asked to re-test one time during the same visit if the information collected is bad because of movement or if the device did not work.
The results of the LightTouch test will be compared with the results of your colposcopy and biopsy. The results of the LightTouch test test will not be used to plan your treatment. If your biopsy results show any abnormal changes, your doctor will discuss treatment options with you.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Procedure: Spectroscopy and Digital Imaging
Procedure: Spectroscopy and Digital Imaging
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to read or understand and give informed consent
* Scheduled for colposcopy
* Pap test within 120 days
* Willing to undergo a Pap test and HPV test on day of study
Exclusion Criteria
* Menstruating on the day of colposcopy and CNDS test
* Radiation therapy to her genitourinary system within 1 year
* Prior hysterectomy
* Congenital anatomical cervical variant (e.g., double cervix)
* Friable cervix at the time of the study (i.e., a cervix that bleeds easily upon minimal contact or trauma)
* Post-coital or other significant bleeding at the time of the exam
* Excessive cervical mucous or discharge that cannot be removed and is significant enough, in the opinion of the investigator, to interfere with a Pap test or colposcopy, resulting from inflammatory, bacterial or other sources
* History of any photosensitizing disease or other disease affected by Ultra-violet radiation, (e.g., pophyria, Lupus Erythematosus).
* Undergoing phototherapy
* Recent use of photosensitizing agents, such as fluoroquinolones or retinoids).
* Patients who are pregnant are not eligible for this study.
16 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Guided Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emory University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lisa Flowers, MD
Role: PRINCIPAL_INVESTIGATOR
Emory University/Grady Hospital System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arkansas
Little Rock, Arkansas, United States
Orange Coast/Saddleback
Laguna Beach, California, United States
Saint Francis Hospital
Hartford, Connecticut, United States
University of Miami
Miami, Florida, United States
Grady Memorial Hospital
Atlanta, Georgia, United States
Medical College of Georgia
Augusta, Georgia, United States
University of Texas
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GT1
Identifier Type: -
Identifier Source: org_study_id